Trial of NovoSeven® in Haemophilia - Joint Bleeds

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Anti-inhibitor coagulant complex

Criteria

Inclusion Criteria:

• Diagnosis of hemophilia A or B with inhibitors to factor VIII or IX, respectively